AAVXF — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
| Jun 2025 | 0 | — | -46,496,000 | -48,414,000 | 119,641,000 | 60,946,000 | 167,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,130,000
Investing CF
$-8,193,000
Financing CF
$547,307,000
CapEx
$-243,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.56
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-738,482,000
Inventory
—
Receivables
$10,495,000
ST Investments
$13,698,000
EBIT TTM
$-302,711,000
Pretax Income TTM
$-330,254,000
Interest Exp TTM
$27,543,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,920,000
EBITDA
$-254,004,000
Free Cash Flow
$-114,471,872
Enterprise Value
$10,564,133,888
Total Cash
$491,552,000
Total Debt
$34,211,000
Shares Out
87,160,669
Trailing EPS
$-5.25
Book Value
$6.19
ROE
-157.1%
ROA
-44.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | — | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | — | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | — | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | — | -53,936,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1188.58 | — |
| JNJ | JOHNSON & JOHNSON | $618.61B | $256.98 | — |
| ABBV | AbbVie Inc. | $438.31B | $248.08 | — |
| NVSEF | NOVARTIS AG | $305.29B | $160.00 | — |
| MRK | Merck & Co., Inc. | $305.12B | $123.54 | — |
News headlines (Yahoo Finance, 1h cache)
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
2026-07-10 13:55 · Yahoo
Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma
2026-07-10 13:35 · Yahoo
3 Soaring Stocks That May Have More Upside Ahead
2026-07-07 23:35 · Yahoo
Abivax: Wall Street Catches Up to the Data
2026-07-07 16:25 · Yahoo
Abivax Announces Closing of $920 Million Public Offering
2026-07-06 20:05 · Yahoo
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
2026-07-06 15:12 · Yahoo
Is ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?
2026-07-03 23:32 · Yahoo
ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds
2026-07-02 10:30 · Yahoo
Abivax jumps as fully exercised option lifts share-sale haul to $920 million
2026-07-02 08:20 · Yahoo
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
2026-07-02 06:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.